FDA APPROVES FIRST NEW DRUG UNDER INTERNATIONAL COLLABORATION, A TREATMENT OPTION FOR PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER
As part of Project Orbis, the U.S. Food and Drug Administration approved Tukysa (tucatinib) in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of adult patients with advanced forms of HER2-positive breast cancer that can’t be removed with surgery, or has spread to other parts of the body, including the brain, and who have received […]
